“In the study, researchers analyzed data from 48 children and teens, ages 3 to 16, with fragile X syndrome, one of the most common forms of inherited intellectual disability. Participants took either the drug or the placebo for three months, and then switched to the other arm of the study, a design known as a double-blind cross-over clinical trial.
Minocycline significantly improved scores on the Clinical Global Impression rating scale, a seven-point measure used to assess symptom severity and response to treatment, lead investigator Randi Hagerman, medical director of the MIND Institute at the University of California, Davis, reported at the conference.
The researchers also saw improvement on the anxiety and mood subscales of the visual analog scale, which is designed to measure conditions such as pain. Because it is a subjective test, it is typically used to measure changes in an individual.
In the trial, the researchers did not see significant differences between placebo and drug treatments in language or aggression scales of this test, nor in the aberrant behavior checklist, another test used to assess treatment effects. The drug seems to be safe and well tolerated, Hagerman says.”
Anti-inflammatory and neuroprotective
“In various models of neurodegenerative disease, minocycline has demonstrated neurorestorative as well as neuroprotective properties. Neurodegenerative diseases such as Huntington’s disease, amyotrophic lateral sclerosis and Parkinson’s disease have shown a particularly beneficial response to minocycline in research studies; an antipsychotic benefit has been found in people schizophrenia and minocycline is proposed as a possible addon therapy for some schizophrenics. Current[when?] research is examining the possible neuroprotective and anti-inflammatory effects of minocycline against progression of a group of neurodegenerative disorders including multiple sclerosis (MS), rheumatoid arthritis (RA), amyotrophic lateral sclerosis (ALS), Huntington’s disease, and Parkinson’s disease”
Further Links and readings
Minocycline to Treat Childhood Regressive Autism
MIND Institute – University of California Davis
“The UC Davis MIND Institute (Medical Investigation of Neurodevelopmental Disorders) is a collaborative international research center, committed to the awareness, understanding, prevention, care, and cure of neurodevelopmental disorders.
In 1998, six visionary families, five who have sons with autism, helped found the UC Davis MIND Institute. These founders are the Beneto, Gardner, Hayes, Rollens, Tsakopoulos, and Vismara families. Their vision? To bring experts from neuroscience to education, from molecular biology to developmental pediatrics, from occupational therapy to psychiatry, to work together toward a common goal: curing neurodevelopmental disorders, starting with autism. Our research projects have since expanded to include Down Syndrome, Tourette Syndrome, Fragile X Syndrome, Attention-Deficit/Hyperactivity Disorder (ADHD) and Chromosome 22q11.2 Deletion Syndrome.”